Message Board
Recently, ACCURATE announced the completion of a Pre-B round of financing of RMB 100 million. In the face of the epidemic and capital competition, ACCURATE has raised hundreds of millions of yuan in just two years, further consolidating its position as the leader of the organoid circuit! This round of financing is led by Fortune Capital, Guangzhou Jinkong Fund, GDD Industry Fund Investment Group, Wanlian Securities, Zhonghe Anke investment, Funway Capital and other original investment institutions continue to invest.
Dr. Huang Min, founder of the company, said that this round of financing reflects investors' firm confidence in the development of the industry and the enterprise. CCM will continue to increase the R&D of core technologies and products and investment in talents, build a technology platform for the whole life cycle of organoids, promote breakthroughs and upgrades of core technologies, and focus on organoid biomaterials, organoid chips and artificial intelligence systems to form a product matrix and industrial chain layout. At the same time, ACCURATE will continue to deepen business transformation and market expansion. In the direction of precision therapy, ACCURATE will provide standardized solutions for clinical patients. In the field of new drug research and development, ACCURATE is committed to solving the unmet market and realizing the corner overtaking of new drug research and development. Centering on the revolutionary technology of organoids, ACCURATE will accelerate the strategic layout and continue to lead the technological development and commercial transformation of organoids!
Fortune Capital said organoid technology has broad application prospects and commercial potential in the fields of clinical drug guidance and new drug research and development. With profound technology and data accumulation in this field, ACCURATE International has built the world's leading organoid technology platform. It was recognized as the Guangdong Engineering and Technology Research Centre of Organoid and participated in the release of the world's first expert consensus on the clinical application of organoids. At the same time, the founding team is excellent, complementary, strong execution, and has a very clear strategic plan for the future development. This is the first time for Fortune Capital in the field of organoids, will firmly work hand in hand with the enterprise and grow together. We are looking forward to working with ACCURATE to lead the organoid technology breakthrough and product upgrade in the future, and bring good news to cancer patients!
Guangzhou Jinkong Fund said that Guangzhou Jinkong Fund attaches great importance to the investment and layout of the biomedical track, especially the segmented fields such as IVD. At present, Guangzhou Jinkong Fund has become the realist of DAAN Gene, and Guangzhou Jinkong Fund also focuses on the investment of high-quality ID projects including Kangliming, which have grown into the leading enterprises of each segmented track. ACCURATE is another important layout of Guangzhou Jinkong Fund in the field of precision therapy. With the gradually mature application of organoid drug sensitivity screening in the field of precision therapy, ACCURATE, as the most advanced enterprise in the field of organoid technology, channels and certification, will fully enjoy the dividends of industry development and grow into another leading enterprise in the field of precision therapy. We look forward to strengthening cooperation and interaction between the two sides to push organoid technology into clinical practice as soon as possible and benefit society.
According to GDD Industry Fund Investment Group, organoid technology is a cutting-edge innovative life technology with rapid development in recent years, which has immeasurable commercial potential in clinical application and drug development. As the first company to enter this circuit, ACCURATE International is the leader among the high-tech enterprises that have grown up in Guangzhou. As a local investment institution, GDD Industry Fund Investment Group will spare no effort to support the continuous expansion and strengthening of enterprises like ACCURATE, and make joint efforts for the status and reputation of Guangzhou as an international biomedical technology research and development center.
Wanlian Tianze, a private equity fund subsidiary of Wanlian Securities, and Wanlian Guangsheng, an investment subsidiary of Wanlian Securities, expressed their great pleasure to participate in this round of financing of ACCURATE. ACCURATE is an innovative biomedical enterprise with organ-like technology as its core. We are optimistic about the company's first-mover advantage in the field of organ-like segmentation, and the management team with Professor Deng Chuxia and Dr. Huang Min as its core has strong executive force. After several years of development, the company has built a relatively complete technical platform for organoid culture, AI image quality control, high-efficiency drug sensitivity detection, etc. Especially, based on the previous large cohort clinical research and application data of organoids with the largest number of samples in the world, the company is building a big data center for organoids. It is bound to effectively promote the application of organogen-related products in clinical and pharmaceutical companies in the field of new drug development.
Funway Capital expressed its congratulations on the successful completion of the new round of financing. As the lead investor in the last round, Funway Capital's continued investment to support the development of the enterprise in this round represents Funway Capital's recognition of the future and value of the company. We are firmly optimistic about the broad prospect and market application of the organoid industry, its diagnosis and treatment AIDS for patients and the acceleration of preclinical research and development for pharmaceutical companies. As a leading company in the industry, we look forward to the rapid growth of our business, the expansion of our visibility at the capital level, the deeper influence in the medical field, and the ultimate embodiment of our corporate social responsibility and medical mission. Come on, ACCURATE!